<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03703856</url>
  </required_header>
  <id_info>
    <org_study_id>R01AG059640-01</org_study_id>
    <nct_id>NCT03703856</nct_id>
  </id_info>
  <brief_title>Biomarker Predictors of Memantine Sensitivity in Patients With Alzheimer's Disease</brief_title>
  <official_title>Biomarker Predictors of Memantine Sensitivity in Patients With Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Diego</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Diego</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The effects of the medication, memantine, on brain functions and the symptoms of Alzheimer's
      Disease will be tested
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 31, 2019</start_date>
  <completion_date type="Anticipated">August 2023</completion_date>
  <primary_completion_date type="Anticipated">August 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline measure in Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-cog) at 8, 16 and 24 weeks</measure>
    <time_frame>0, 8, 16, 24 weeks</time_frame>
    <description>measures cognitive ability</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline measure in Neuropsychiatric Inventory-Questionnaire (NPI-Q) at 8, 16 and 24 weeks</measure>
    <time_frame>0, 8, 16, 24 weeks</time_frame>
    <description>measures behavioral symptoms</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change from baseline measure in Geriatric Depression Scale (GDS) at 8, 16 and 24 weeks</measure>
    <time_frame>0, 8, 16, 24 weeks</time_frame>
    <description>measures behavioral symptoms</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">88</enrollment>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>Memantine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Memantine</intervention_name>
    <description>Phase 1 will test the acute effects of memantine (20 mg po) vs. placebo (PBO) on early auditory information processing measures in 88 carefully characterized patients with mild-to-moderate severity AD who are not currently taking AD medications. From this &quot;challenge&quot; test, a set of &quot;early auditory information processing memantine sensitivity&quot; measures will be derived for each patient. In Phase 2, all patients will begin an open-label trial of memantine monotherapy, titrated to 10 mg bid, with outcome measures collected after 8, 16 and 24 weeks of treatment. Medication adjustments are not restricted, and response heterogeneity is anticipated.</description>
    <arm_group_label>Memantine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Phase 1 will test the acute effects of memantine (20 mg po) vs. placebo (PBO) on early auditory information processing measures in 88 carefully characterized patients with mild-to-moderate severity AD who are not currently taking AD medications. From this &quot;challenge&quot; test, a set of &quot;Early auditory information processing P memantine sensitivity&quot; measures will be derived for each patient. In Phase 2, all patients will begin an open-label trial of memantine monotherapy, titrated to 10 mg bid, with outcome measures collected after 8, 16 and 24 weeks of treatment. Medication adjustments are not restricted, and response heterogeneity is anticipated.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion:

          1. Alzheimer's Disease Research Center-confirmed diagnosis of AD

          2. Mini-Mental State Examination (MMSE) score 10-22 OR a Montreal Cognitive Assessment
             (MOCA) score of 15-24

          3. Age 50-80 y

          4. Knowledgeable caregiver

          5. Ambulatory

          6. Medically stable;

          7. Audiometric testing (detection &lt; 40 db(A) at 1000 Hz)

          8. Informed consent

        Exclusion:

          1. Active systemic illness (e.g. heart disease, liver failure, renal insufficiency,
             cancer, HIV, tuberculosis, Hepatitis C)

          2. Current psychiatric or neurologic illness other than AD

          3. History of vascular disease, myocardial infarction, cerebrovascular accidents,
             transient ischemic attack, seizure, head injury with loss of consciousness; substance
             dependence (including alcohol and Opioid)

          4. Past treatment with memantine; unable to tolerate acetylcholinesterase inhibitor

          5. Investigational drug treatment &lt; 30 d of screening

          6. Current meds: amantadine, riluzole, other pro-cognitive medication, opioids

          7. Positive urine toxicology for non-prescribed psychoactive substance

          8. Actively enrolled in cognitive remediation therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Neal Swerdlow, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCSD</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joyce Sprock</last_name>
    <phone>(619) 471-9455</phone>
    <email>jsprock@ucsd.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinical Teaching Facility (CTF-B102) at UCSD Medical Center</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jo Talledo, B.A.</last_name>
      <phone>619-543-3093</phone>
      <email>atalledo@ucsd.edu</email>
    </contact>
    <investigator>
      <last_name>Neal R. Swerdlow, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>October 9, 2018</study_first_submitted>
  <study_first_submitted_qc>October 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 12, 2018</study_first_posted>
  <last_update_submitted>March 5, 2020</last_update_submitted>
  <last_update_submitted_qc>March 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Diego</investigator_affiliation>
    <investigator_full_name>Neal R. Swerdlow, M.D., Ph.D.</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Alzheimer's Disease</keyword>
  <keyword>Alzheimer Disease</keyword>
  <keyword>Alzheimer</keyword>
  <keyword>AD</keyword>
  <keyword>Alzheimer's</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Memantine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

